BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Milsaperidone (VHX-896) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Milsaperidone (VHX-896)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06830044-9305@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Milsaperidone (VHX-896): Phase 3 readout est. (NCT06830044)
DESCRIPTION:Milsaperidone (VHX-896)\, phase 3\, Major Depressive Disorder.\
 nStudy: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive T
 herapy in Patients With Major Depressive Disorder\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 lsaperidone-vhx-896#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06830044
URL:https://assetmemo.bio/drug/milsaperidone-vhx-896#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
